Polyhydroxy substituted arbutin derivative and microbial conversion preparation method and application thereof

Through microbial transformation technology, the conversion of urfolol into polyhydroxy substituted derivatives has solved the uncertainty of solubility and structural modification in anti-tumor research, and obtained significant anti-tumor active ingredients for the preparation of anti-tumor. Drugs, especially for the treatment of a variety of cancers.

CN118930600AActive Publication Date: 2024-11-12NANTONG UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410998336.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

The poor solubility, low bioavailability and uncertainty of urfolol limit its application in pharmacological research, especially the development of anti-tumor properties.

Method used

Through microbial transformation technology, urfolol is converted into 7β, 15α, 19α, 21α-tetrahydroxy, 7β, 15α, 20β, 21β-tetrahydroxy and 7β, 15α, 20β, 23-tetrahydroxy and 7β, 15α, 20β, 23-tetrahydroxy Hydroxyurfol was purified by reverse phase silica gel column chromatography and reverse phase high performance liquid chromatography to obtain polyhydroxy substituted urfolol derivatives with significant anti-tumor activity.

Benefits of technology

The obtained polyhydroxy aurfolol derivatives showed significant anti-tumor activity, which can effectively inhibit the growth of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer cells, and can kill leukemia resistance. cell.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004960883620000021
    Figure BDA0004960883620000021
  • Figure BDA0004960883620000035
    Figure BDA0004960883620000035
  • Figure BDA0004960883620000041
    Figure BDA0004960883620000041
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and discloses a polyhydroxy substituted arbutin derivative as well as a microbial conversion preparation method and application thereof. According to the preparation method, a microbial conversion technology is utilized, arbutin is taken as a substrate, after catalytic conversion is carried out by adopting microbial lysomyza, hydroxyl groups are introduced into a plurality of positions of an arbutin mother nucleus in a regioselective and stereoselective manner, so that the polyhydroxy substituted arbutin derivative with a novel structure is obtained. An in-vitro anti-tumor cell test proves that the polyhydroxy substituted arbutin derivative obtained by the invention has remarkable anti-tumor activity, can be used as an active ingredient of an anti-tumor drug, and has wide application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to a class of polyhydroxy substituted ursodiol derivatives and a microbial transformation preparation method and application thereof. Background Art

[0002] Ursolic acid, also known as ursolic acid, is a natural ursane-type pentacyclic triterpenoid compound widely distributed in olives, including olive leaves, bark, fruit and extra virgin olive oil. The content of ursolic acid is one of the important indicators for people to evaluate the quality of olive oil. It can also be isolated from different parts of plants such as bayberry, camellia oil, oleander, lavender, apple, etc. Preliminary studies have shown that ursolic acid has a variety of pharmacological activities, including anti-inflammatory, cardiotonic, anti-arrhythmic, and anti-tumor properties, and can promote the healing of skin wounds.

[0003] However, due to the poor solubility, low bioavailability, and the limited number of hydrogen bond donors in the mother nucleus and the limited number of rotatable bonds in the rigid skeleton of ursolic alcohol, further chemical and biological research on it is limited. In order to improve these characteristics of ursolic alcohol, researchers mainly use chemical synthesis and biotransformation methods to modify the structure of ursolic alcohol. Conventional chemical synthesis methods are costly, and it is particularly difficult to introduce functional groups on saturated CH bonds. Microbial transformation is a simple and effective natural compound structure modification technology that can introduce functional groups regioselectively and stereoselectively, with the advantages of high efficiency, economy, and environmental protection, which is difficult to achieve with conventional chemical modification. As an efficient modification tool, microbial transformation technology can modify the structure of natural active compounds with different skeletons and has been widely used in the structural modification of various compounds. On the one hand, the transformation products obtained by microbial transformation can obtain derivatives with stronger biological activity and be directly used in drug research and development. On the other hand, the newly introduced chemically active groups on the mother nucleus after microbial transformation increase the sites for chemical modification and transformation, thereby solving the problem of few reaction sites for the organic chemical preparation of derivatives of triterpenoid compounds. However, compared with chemical synthesis, microbial transformation methods are highly random, and the results of transformation cannot be predicted like chemical synthesis, nor can they be purposefully designed. At the same time, even similar substrates can have very significant differences in the products obtained after catalytic transformation by the same strain or different strains. The same substrate can also have very significant differences in the transformation products obtained after transformation by different strains. Therefore, it is crucial to select the appropriate strain when using microbial transformation methods to modify the structure of compounds. Summary of the invention

[0004] In view of this, the purpose of the present invention is to provide a series of polyhydroxy substituted ursodiol derivatives and microbial transformation preparation methods thereof, and these polyhydroxy substituted ursodiol derivatives can be used to prepare anti-tumor drugs.

[0005] The present invention provides a series of polyhydroxy substituted ursoline derivatives, the polyhydroxy substituted ursoline derivatives are 7β,15α,19α,21α-tetrahydroxy ursoline, 7β,15α,20β,21β-tetrahydroxy ursoline and 7β,15α,20β,23-tetrahydroxy ursoline, the structures of which are shown in Formulas I to III respectively:

[0006]

[0007] The present invention also provides a method for preparing the above-mentioned polyhydroxy-substituted ursodiol derivatives by microbial transformation, comprising the following steps:

[0008] 1) fermenting and culturing a microorganism, adding ursolic alcohol, and then performing transformation culture, removing mycelium to obtain a fermentation liquid, wherein the microorganism is Circinella muscae CGMCC3.2695;

[0009] 2) extracting the fermentation broth to obtain a transformant;

[0010] 3) purifying the transformation product by reverse phase silica gel column chromatography, wherein the reverse phase silica gel column chromatography purification adopts a methanol-water two-phase system gradient elution, and collecting and merging the components;

[0011] 4) Purifying the components by reverse phase high performance liquid chromatography to obtain 7β,15α,19α,21α-tetrahydroxyurbutol, 7β,15α,20β,21β-tetrahydroxyurbutol and 7β,15α,20β,23-tetrahydroxyurbutol.

[0012] The present invention also provides the use of the above-mentioned polyhydroxy substituted ursodiol derivatives or the polyhydroxy substituted ursodiol derivatives prepared by the above-mentioned microbial transformation preparation method in the preparation of anti-tumor drugs, wherein the tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.

[0013] The present invention also provides the use of the above-mentioned polyhydroxy substituted ursodiol derivative or the polyhydroxy substituted ursodiol derivative prepared by the above-mentioned microbial transformation preparation method in the preparation of a drug for killing leukemia drug-resistant cells.

[0014] The present invention also provides an anti-tumor drug, the active ingredient of which is the above-mentioned polyhydroxy substituted ursool derivative or a pharmaceutically acceptable salt thereof; the polyhydroxy substituted ursool derivative is one or more of 7β,15α,19α,21α-tetrahydroxy ursool, 7β,15α,20β,21β-tetrahydroxy ursool and 7β,15α,20β,23-tetrahydroxy ursool; the tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.

[0015] Compared with the prior art, the present invention utilizes the catalytic action of microbial enzymes to regioselectively and stereoselectively introduce a hydroxyl group or a carbonyl group at the 7β position, 15α position, 19α position, 20β position, 21β(α) position or 23 position of the ursolic acid parent nucleus, thereby obtaining novel polyhydroxy substituted ursolic acid derivatives of formula I to formula III. In vitro anti-tumor cell tests have confirmed that the compounds of formula I to formula III have significant anti-tumor activity, can be used as active ingredients of anti-tumor drugs, and have a wide range of uses. DETAILED DESCRIPTION

[0016] To further illustrate the present invention, the preparation method of the polyhydroxy ursodiol derivatives provided by the present invention and the application thereof in the preparation of anti-tumor drugs are described in detail below in conjunction with examples.

[0017] Example 1: Preparation of compounds of formula I to formula III

[0018] The substrate ursolic acid is transformed by using Circinella muscae CGMCC 3.2695 to prepare compounds with the structural formulas of Formula I to Formula III. The preparation process of the compounds is as follows:

[0019] After 500 mg of ursolic acid was transformed by Fly Roller Mold for 7 days, the bacterial liquid was extracted with an equal volume of ethyl acetate to obtain about 0.92 g of the transformation crude extract. The transformation crude extract was separated by ODS-C18 column chromatography, methanol: water gradient elution (20:80, 30:70, 60:40, 80:20, 100:0), and combined after HPLC analysis to obtain combined components Fr.1-Fr.3. Component Fr.2 was purified by reverse phase high performance liquid chromatography, acetonitrile-water (55:45, V / V), flow rate 3.0 mL / min, detection wavelength 203 nm. The transformation products with structural formulas of Formula I-Formula III were obtained. The mass spectra and spectroscopy data of compounds Formula I-Formula III are shown below.

[0020] Compound Ⅰ: 7β,15α,19α,21α-tetrahydroxyarbutol; optical rotation High resolution mass spectrum m / z 529.3506[M+Na] +(calcd.C 30 H 50 O 6 Na, 529.3505); the H NMR and C NMR data are shown in Table 2.

[0022] Compound II: 7β,15α,20β,21β-tetrahydroxyarbutol; optical rotation :+11.3°(c=0.1,MeOH); high resolution mass spectrum m / z529.3507[M+Na] + (calcd.forC 30 H 50 O 6 Na, 529.3505); the H NMR and C NMR data are shown in Table 2.

[0023] Compound III: 7β,15α,20β,23-tetrahydroxyarbutol; optical rotation High resolution mass spectrum m / z 529.3506[M+Na] + (calcd.for C 30 H 50 O 6 Na, 529.3505); the H NMR and C NMR data are shown in Table 1.

[0024] Table 1 H NMR and C NMR data of compounds of formula I to formula III

[0025]

[0026]

[0027] The above results show that the structures of the obtained compounds of formula I to formula III are correct.

[0028] Example 2: Antitumor activity of compounds of formula I to formula III

[0029] 1) Experimental Materials

[0030] Instruments and reagents: CO 2 Incubator (Jouan IGO150); fluorescence inverted microscope (Olympus IX51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotechnology Research Institute), RPM I 1640 medium (GibcolBRL), RNaseA, fetal bovine serum, dimethyl sulfoxide (DMSO), trypsin (Shanghai Bioengineering Co., Ltd.).

[0031] The tumor cell lines used for the test: Hela cells (human cervical cancer cells), K562 cells (human leukemia cells), K562 / ADR cells (human leukemia resistant cells), SH-SY5Y cells (human neuroblastoma cells), Du-145 (human prostate cancer cells), HePG2 cells (human liver cancer cells), MCF-7 cells (human breast cancer cells), CT26 cells (colon cancer cells), were purchased from the Institute of Oncology, Chinese Academy of Medical Sciences.

[0032] Test samples: arbutin and the compounds of formula I to formula III synthesized in Example 1, with a purity of more than 95%; at the same time, cisplatin was selected as a positive control drug, and each compound was dissolved in DMSO and then diluted.

[0033] 2) Experimental methods

[0034] The MTT method was used to determine the half inhibition rate IC of each test compound on tumor cell lines. 50 Value: Take tumor cells in the logarithmic growth phase and adjust the cell concentration to 5×10 5 / mL, inoculated in 96-well culture plates, drug treatment group and cell control group added 100μL cell suspension per well, each group set up 3 replicates, blank control group only added RPM I 1640 full culture medium, 100μL per well, set up 3 replicates. 96-well culture plates were placed at 37℃, 5% CO 2 After 24 hours of incubation in the incubator, different concentrations of the test samples were added to make the final concentration 0.1-100 μM, and the culture was continued for 72 hours. The absorbance (A) value at 570 nm was measured on a microplate reader according to the MTT method, and the inhibition rate was calculated [inhibition rate = (1-A value of the experimental group / A value of the control group) × 100%]. The experiment was repeated 3 times. SPSS11.5 software was used to make a regression equation to calculate the half-maximal inhibitory concentration (IC) of each test sample on tumor cells for 72 hours. 50 ).

[0035] 3) Experimental results

[0036] According to the MTT test results, calculate the IC of the test sample for the above cells 50 The results are shown in Table 2.

[0037] Table 2 In vitro cytotoxic activity screening results of test samples

[0038]

[0039]

[0040] The results show that the compounds of formula I to formula III of the present invention have good anti-tumor activity and can be used as active ingredients of anti-tumor drugs. At the same time, the compounds of formula I to formula III of the present invention can effectively kill human leukemia resistant cells.

[0041] Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A polyhydroxy substituted ursodiol derivative, characterized in that: The ursool derivative is one of 7β,15α,19α,21α-tetrahydroxyursool, 7β,15α,20β,21β-tetrahydroxyursool and 7β,15α,20β,23-tetrahydroxyursool; The 7β,15α,19α,21α-tetrahydroxyarbutol has a structure of Formula I: The 7β,15α,20β,21β-tetrahydroxyursoline has a structure of Formula II: The 7β,15α,20β,23-tetrahydroxyarbutol has a structure of formula III:

2. A method for preparing the polyhydroxy-substituted ursodiol derivatives by microbial transformation according to claim 1, characterized in that: The following steps are involved: 1) fermenting and culturing a microorganism, adding ursolic alcohol, then performing transformation culture, removing mycelium to obtain a fermentation liquid, wherein the microorganism is Circinella muscae CGMCC3.2695; 2) extracting the fermentation broth to obtain a transformant; 3) Purifying the transformation product by reverse phase silica gel column chromatography, wherein the reverse phase silica gel column chromatography purification adopts a methanol-water two-phase system gradient elution, and after collecting and combining the components, purifying them by reverse phase high performance liquid chromatography to obtain the polyhydroxy substituted ursodiol derivative.

3. Use of the polyhydroxy substituted urbutol derivative according to claim 1 or the polyhydroxy substituted urbutol derivative prepared by the preparation method according to claim 2 in the preparation of anti-tumor drugs.

4. The use according to claim 3, characterized in that: The tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.

5. The use according to claim 3, characterized in that: The anti-tumor drug is a drug used to kill leukemia drug-resistant cells.

6. A pharmaceutical composition for anti-tumor, characterized in that: The active ingredient of the pharmaceutical composition is an ursolic acid derivative or a pharmaceutically acceptable salt thereof; the ursolic acid derivative is one or more of 7β,15α,19α,21α-tetrahydroxyursolic acid, 7β,15α,20β,21β-tetrahydroxyursolic acid and 7β,15α,20β,23-tetrahydroxyursolic acid; and the tumor is one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.

7. The pharmaceutical composition according to claim 6, characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient is one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

Citation Information

Patent Citations

  • Application of ursolic acid derivatives in preparation of antitumor drugs

    CN113134006A

  • Asiatic acid microbial conversion derivative as well as preparation method and application thereof

    CN116284199A

  • Urbutic derivative, microbial conversion preparation method and application

    CN116693593A